Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article (71)

Advertisement

Free access | 10.1172/JCI110020

Interactions between Antibiotics and Human Neutrophils in the Killing of Staphylococci: STUDIES WITH NORMAL AND CYTOCHALASIN B-TREATED CELLS

Richard K. Root, Raul Isturiz, Abdolghader Molavi, Julia A. Metcalf, and Harry L. Malech

Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510

Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut 06510

Find articles by Root, R. in: PubMed | Google Scholar

Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510

Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut 06510

Find articles by Isturiz, R. in: PubMed | Google Scholar

Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510

Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut 06510

Find articles by Molavi, A. in: PubMed | Google Scholar

Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510

Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut 06510

Find articles by Metcalf, J. in: PubMed | Google Scholar

Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510

Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut 06510

Find articles by Malech, H. in: PubMed | Google Scholar

Published January 1, 1981 - More info

Published in Volume 67, Issue 1 on January 1, 1981
J Clin Invest. 1981;67(1):247–259. https://doi.org/10.1172/JCI110020.
© 1981 The American Society for Clinical Investigation
Published January 1, 1981 - Version history
View PDF
Abstract

Normal and antibiotic-pretreated staphylococci were incubated with human neutrophils to determine the interactions between cells and antimicrobials in the killing of the organisms. Staphylococcus aureus 502A pretreated during log-phase growth with subinhibitory (¼ minimum inhibiting concentration) (MIC) concentrations of penicillin G were more susceptible to killing by normal neutrophils than untreated bacteria (intracellular survival 0.17±0.04 vs. 1.5±0.38%, mean±SEM, respectively, at 35 min in 14 experiments; P < 0.01 by t test). Furthermore, this enhanced susceptibility to killing was observed even when phagosome formation was inhibited by cytochalasin B (65.6±4.6% pencillintreated vs. 30.5±4.5% untreated killed at 30 min in 14 experiments, P < 0.001). Pretreatment of S. aureus with vancomycin similarly enhanced susceptibility to killing by cytochalasin B-treated polymorphonuclear leukocytes (PMN), whereas pretreatment with gentamicin did not.

The enchancement of killing by pretreatment with cell wall-active antibiotics was present in a dose-response fashion to 1/16th the MIC. It required specific antimicrobial activity; i.e., penicillin activity was inhibited by penicillinase or by incubation with bacteria at 4°C. It also required active cellular metabolism and intact neutrophils. For antibiotic-pretreated bacteria to be killed by normal and cytochalasin B-treated cells, phagocytosis or binding to the cells was essential via a serum opsonindependent mechanism. In experiments with the cytochalasin B-treated cells, all bound penicillin-treated bacteria were killed vs. only a fraction (70%) of the bound untreated bacteria. Penicillin in 10 times the MIC had no direct effects on PMN phagocytic, metabolic, or microbicidal functions against a nonsusceptible organism, Candida albicans.

The results indicate a cooperative effect between cell wall-active antibiotics at low concentrations and human PMN in the killing of staphylococci. The model establishes conditions for the study of the mechanisms involved in the cooperation of these bactericidal systems.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 247
page 247
icon of scanned page 248
page 248
icon of scanned page 249
page 249
icon of scanned page 250
page 250
icon of scanned page 251
page 251
icon of scanned page 252
page 252
icon of scanned page 253
page 253
icon of scanned page 254
page 254
icon of scanned page 255
page 255
icon of scanned page 256
page 256
icon of scanned page 257
page 257
icon of scanned page 258
page 258
icon of scanned page 259
page 259
Version history
  • Version 1 (January 1, 1981): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article (71)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts